Intellia Therapeutics reported $67.7 million in revenue for FY 2025 but widened its net loss to $412.7 million as it advances gene-editing programs.
pipeline. The company, however, posted a net loss of $412.7 million, reflecting high R&D costs for programs targeting hereditary angioedema and transthyretin amyloidosis
The biotech firm maintains a low debt-to-equity ratio of 0.1x, signaling a conservative balance sheet. Intellia’s collaboration with Regeneron Pharmaceuticals remains central to its strategy, focusing on neurological and muscular disease therapies.
Shares of Intellia (NASDAQ:NTLA) operate in a high-risk, high-reward segment, competing with firms like Omeros (NASDAQ:OMER) in the orphan disease and oncology space.